These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8566154)

  • 1. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
    Valverde O; Blommaert AG; Fournié-Zaluski MC; Roques BP; Maldonado R
    Eur J Pharmacol; 1995 Nov; 286(1):79-93. PubMed ID: 8566154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
    Maldonado R; Valverde O; Ducos B; Blommaert AG; Fournie-Zaluski MC; Roques BP
    Br J Pharmacol; 1995 Mar; 114(5):1031-9. PubMed ID: 7780637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
    Noble F; Blommaert A; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1995 Jan; 273(1-2):145-51. PubMed ID: 7737308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses.
    Maldonado R; Derrien M; Noble F; Roques BP
    Neuroreport; 1993 Jul; 4(7):947-50. PubMed ID: 8369487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    Coudoré-Civiale MA; Méen M; Fournié-Zaluski MC; Boucher M; Roques BP; Eschalier A
    Br J Pharmacol; 2001 May; 133(1):179-85. PubMed ID: 11325808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone.
    Le Guen S; Mas Nieto M; Canestrelli C; Chen H; Fournié-Zaluski MC; Cupo A; Maldonado R; Roques BP; Noble F
    Pain; 2003 Jul; 104(1-2):139-48. PubMed ID: 12855323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
    Xu XJ; Elfvin A; Hao JX; Fournié-Zaluski MC; Roques BP; Wiesenfeld-Hallin Z
    Neuropeptides; 1997 Jun; 31(3):287-91. PubMed ID: 9243527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.
    Noble F; Turcaud S; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1992 Nov; 223(1):83-9. PubMed ID: 1478260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus properties.
    Hutcheson DM; Subhan F; Pache DM; Maldonado R; Fournié-Zaluski M; Roques BP; Sewell RD
    Eur J Pharmacol; 2000 Aug; 401(2):197-204. PubMed ID: 10924927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
    Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
    J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of opioid-induced conditioned place preference by the selective serotonin reuptake inhibitor fluoxetine.
    Subhan F; Pache DM; Sewell RD
    Eur J Pharmacol; 2000 Feb; 390(1-2):137-43. PubMed ID: 10708717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
    Ruiz F; Fournié-Zaluski MC; Roques BP; Maldonado R
    Br J Pharmacol; 1996 Sep; 119(1):174-82. PubMed ID: 8872371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
    Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
    Noble F; Soleilhac JM; Soroca-Lucas E; Turcaud S; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1992 Apr; 261(1):181-90. PubMed ID: 1560364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists.
    Singh L; Field MJ; Hill DR; Horwell DC; McKnight AT; Roberts E; Tang KW; Woodruff GN
    Eur J Pharmacol; 1995 Nov; 286(2):185-91. PubMed ID: 8605955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects.
    Smadja C; Maldonado R; Turcaud S; Fournie-Zaluski MC; Roques BP
    Psychopharmacology (Berl); 1995 Aug; 120(4):400-8. PubMed ID: 8539320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.
    Valverde O; Fournie-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1996 Jan; 123(2):119-26. PubMed ID: 8741934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids.
    Valverde O; Fournié-Zaluski MC; Roques BP; Maldonado R
    Eur J Pharmacol; 1996 Sep; 312(1):15-25. PubMed ID: 8891574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.
    Bickerdike MJ; Marsden CA; Dourish CT; Fletcher A
    Eur J Pharmacol; 1994 Dec; 271(2-3):403-11. PubMed ID: 7705440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.